Goldman Sachs
KPTI icon

Goldman Sachs’s Karyopharm Therapeutics KPTI Stock Holding History

Goldman Sachs’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-3,980
Closed -$629K – 7262
2015
Q3 		$629K Sell
3,980
-20
-0.5% -$5.35K ﹤0.01% 4915
2015
Q2 		$1.63M Buy
4,000
+667
+20% +$288K ﹤0.01% 4040
2015
Q1 		$1.53M Buy
+3,333
New +$1.44M ﹤0.01% 4037

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Goldman Sachs's KPTI Position: Q1 2026 in Review

Goldman Sachs opened a new position in Karyopharm Therapeutics (KPTI) in Q1 2026: 947,579 shares worth $5.28M. The stake represents ﹤0.01% of the portfolio and ranks #3642 among its holdings. This is a return to the name: Goldman Sachs previously reported a position in KPTI as recently as Q3 2025.

Goldman Sachs first reported a position in KPTI in Q1 2014 and has held it in 47 quarters since. The position peaked at $37.9M in Q2 2020. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Goldman Sachs held 947,579 shares of Karyopharm Therapeutics worth $5.28M as of Q1 2026.
  • Karyopharm Therapeutics was a new Goldman Sachs position in Q1 2026.
  • Karyopharm Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3642 holding.
  • Goldman Sachs first reported a position in Karyopharm Therapeutics in Q1 2014 and has held it in 47 quarters since.
  • Goldman Sachs's Karyopharm Therapeutics position peaked at $37.9M in Q2 2020.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.